Here are five key notes:
1. DUROLANE is a single-injection joint-fluid osteoarthritis treatment.
2. The technology is based on the NASHA process which yields stabilized hyaluronic acid.
3. DUROLANE is indicated to treat mild to moderate osteoarthritis of the knee in Taiwan.
4. The company is working with sales and marketing company Eulogiums to bring DUROLANE to the market.
5. Bioventus is focused on cost-effective orthobiologics products delivering clinically-proven care.
“We believe that only knee OA products with superior quality can withstand the competitive market in Taiwan and we have confidence that DUROLANE is the one,” said Eulogiums CEO Kenny Liu.
More articles on orthopedic devices:
8 ROSA robots sold in 2016—5 highlights
Benvenue Medical obtains $60M financing: 5 things to know
Mazor sells 25 robotic spine systems in Q4: 5 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
